Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Nuvectis Pharma. The associated price target remains the same with $15.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Joseph Pantginis has given his Buy rating due to a combination of factors related to Nuvectis Pharma’s promising developments with their drug NXP900. The recent completion of a Drug-Drug Interaction study revealed that NXP900, a weak CYP3A inhibitor, can be effectively combined with existing therapies for non-small cell lung cancer (NSCLC) without significant adverse effects. This positions NXP900 as a viable candidate for combination therapies, particularly with EGFR and ALK inhibitors, which are crucial in NSCLC treatment.
Additionally, presentations at AACR ’25 highlighted the robust scientific rationale for NXP900’s clinical exploration. The drug has shown potential in preclinical studies to inhibit tumor growth and enhance the efficacy of existing treatments in resistant cancer models. These findings suggest that NXP900 could play a significant role in overcoming drug resistance in cancer therapy, thereby supporting the positive outlook and Buy rating for Nuvectis Pharma’s stock.